» Authors » Praechompoo Pongtornpipat

Praechompoo Pongtornpipat

Explore the profile of Praechompoo Pongtornpipat including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 94
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Dower W, Park A, Bakker A, Cwirla S, Pongtornpipat P, Williams B, et al.
PLoS One . 2023 Oct; 18(10):e0286834. PMID: 37874823
Interleukin (IL)-7 is broadly active on T-cell populations, and modified versions have been clinically evaluated for a variety of therapeutic applications, including cancer, lymphopenia, and infectious diseases; and found to...
2.
Peters T, Tillotson J, Yeomans A, Wilmore S, Lemm E, Jimenez-Romero C, et al.
Clin Cancer Res . 2018 May; 24(17):4256-4270. PMID: 29844128
The DEAD-box RNA helicase eIF4A1 carries out the key enzymatic step of cap-dependent translation initiation and is a well-established target for cancer therapy, but no drug against it has entered...
3.
Peters T, Li L, Tula-Sanchez A, Pongtornpipat P, Schatz J
Oncotarget . 2016 Aug; 7(39):63362-63373. PMID: 27556513
The PIM family kinases promote growth and survival of tumor cells and are expressed in a wide variety of human cancers. Their potential as therapeutic targets, however, is complicated by...
4.
Amin A, Li L, Rajan S, Gokhale V, Groysman M, Pongtornpipat P, et al.
Oncotarget . 2016 Mar; 7(17):23715-29. PMID: 27009859
The anaplastic lymphoma kinase (ALK) protein drives tumorigenesis in subsets of several tumors through chromosomal rearrangements that express and activate its C-terminal kinase domain. In addition, germline predisposition alleles and...
5.
Amin A, Rajan S, Groysman M, Pongtornpipat P, Schatz J
Biomark Cancer . 2015 Dec; 7(Suppl 2):25-32. PMID: 26688666
Acquired resistance to targeted inhibitors remains a major, and inevitable, obstacle in the treatment of oncogene-addicted cancers. Newer-generation inhibitors may help overcome resistance mutations, and inhibitor combinations can target parallel...
6.
Amin A, Rajan S, Liang W, Pongtornpipat P, Groysman M, Tapia E, et al.
Cancer Res . 2015 May; 75(14):2916-27. PMID: 26018086
The anaplastic lymphoma kinase (ALK) is chromosomally rearranged in a subset of certain cancers, including 2% to 7% of non-small cell lung cancers (NSCLC) and ∼70% of anaplastic large cell...
7.
Fiema B, Harris A, Gomez A, Pongtornpipat P, Lamiman K, Vander Lugt M, et al.
J Vis Exp . 2012 Nov; (68). PMID: 23149907
Unbiased discovery proteomics strategies have the potential to identify large numbers of novel biomarkers that can improve diagnostic and prognostic testing in a clinical setting and may help guide therapeutic...